Using cell secretions to help heal corneal wounds
Phase I Study of Mesenchymal Stromal Cell Secretome for Promoting Corneal Regeneration
This study is looking at how special eye drops made from cells in the body can help heal stubborn corneal wounds that can happen due to diabetes or autoimmune diseases, with the goal of improving vision for those affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-10692838 on NIH RePORTER |
What this research studies
This research investigates the use of secretions from mesenchymal stromal cells (MSCs) to promote healing in patients with non-healing corneal wounds. These wounds can result from various conditions, including diabetes and autoimmune diseases, and often lead to vision loss. The study aims to develop a treatment that utilizes MSC secretome in the form of eye drops to enhance tissue repair and reduce inflammation and scarring. By bridging laboratory findings with clinical application, this trial seeks to provide a new therapeutic option for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old suffering from non-healing corneal wounds due to conditions like diabetes or autoimmune diseases.
Not a fit: Patients with corneal wounds that are not classified as non-healing or those with other unrelated ocular conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that significantly improves healing and reduces complications for patients with chronic corneal wounds.
How similar studies have performed: Previous studies have shown promising results using MSC secretions for tissue repair, indicating a potential for success in this novel application.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Djalilian, Ali R — University of Illinois at Chicago
- Study coordinator: Djalilian, Ali R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.